A Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal Region
2026年7月13日 更新者:Newish Biotech (Wuxi) Co., Ltd.
An Exploratory Clinical Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal Region: Safety and Preliminary Efficacy Observation
This is an open-label, single-center, investigator-initiated exploratory trial evaluating NWRD09 in 10 participants with persistent HPV16 infection in the anal region.
研究概览
详细说明
This is an open-label, single-center, investigator-initiated clinical trial (IIT) designed to evaluate the efficacy, safety, and immunogenicity of NWRD09 in patients with persistent HPV16 infection localized to the anal region.
A total of 10 participants will be enrolled and allocated to two parallel treatment groups.
Participants are assigned to two parallel treatment groups, with one sentinel participant per group.
Sentinel safety observation over 7 days post-first dose precedes enrollment of subsequent participants.
Objectives include assessment of safety/tolerability, HPV16 DNA clearance, cytological regression, histopathological improvement (for baseline AIN1), and cellular immune responses through Week 28.
研究类型
介入性
注册 (估计的)
10
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Dr. Chen Zeyang, MD
- 电话号码:+86-13051555186
- 邮箱:chenzeyang_pku@163.com
学习地点
-
-
-
Beijing、中国
- 招聘中
- Peking University First Hospital
-
接触:
- Dr. Chen Zeyang, MD
- 电话号码:+86-13051555186
- 邮箱:chenzeyang_pku@163.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
接受健康志愿者
不
描述
Inclusion Criteria:
- Female and male, aged 18 to 60 years (inclusive).
- HPV DNA genotyping of anal specimens demonstrates positivity for HPV16, with documented persistence for at least 12 months (≥12 months).
- Histopathological findings show low-grade lesion, inflammation, or no abnormality.
- Adequate organ function within 4 week before the first dose.
- For premenopausal women of childbearing potential: a negative serum pregnancy test within 4 weeks before the first dose. Eligible participants of childbearing potential and their partners must agree to use highly effective contraception throughout the trial and for 6 months after the last study dose.
- Ability to understand the study and voluntarily provide written informed consent (ICF), willingness and ability to communicate effectively with the investigator, and to comply with all protocol-required treatment, examinations, and visits.
Key Exclusion Criteria:
- Any histopathologically confirmed adenocarcinoma/adenocarcinoma in situ (AIS), high-grade cervical, vulvar, vaginal, or anal intraepithelial neoplasia, or invasive cancer.
- Pregnant or breastfeeding women, or those planning to become pregnant during the study period.
- Participation in another clinical trial within 30 days prior to screening, or currently being in the follow-up period of another clinical trial.
- Continuous use (for >1 week) of systemic corticosteroids at a dose equivalent to >10 mg/day of prednisone within 30 days prior to screening, with the exception of hormone replacement therapy and topical administration (e.g., intratracheal, ophthalmic).
- Continuous use (for >1 week) of immunosuppressants (e.g., cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, antilymphocyte globulin) within 30 days prior to screening.
- Receipt of any inactivated or live vaccine within 4 weeks prior to the first dose of study drug.
- Receipt of any AIN-related drug or physical therapy within 4 weeks prior to the first dose.
- History of any therapeutic HPV vaccination (prior receipt of licensed prophylactic HPV vaccines is acceptable).
- Use of blood or blood-related products (including immunoglobulins) within 3 months prior to the first dose, or planned use during the study period.
- History of immunodeficiency or autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, etc.).
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intensive treatment group
|
Each participant will be administered NWRD09 by IM injection
|
|
实验性的:Sparse treatment group
|
Each participant will be administered NWRD09 by IM injection
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence and severity of local and systemic adverse events (AEs).
大体时间:Up to 28 weeks
|
Based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V6.0, adverse events (AEs) and serious adverse events (SAEs) will be monitored.
|
Up to 28 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants with virologically-proven clearance of HPV 16 at week 16.
大体时间:Week 16
|
The number of participants with virologically-proven clearance of HPV 16 at week 16.
|
Week 16
|
|
Proportion of participants with virologically-proven clearance of HPV 16 at week 28.
大体时间:Week 28
|
The number of participants with virologically-proven clearance of HPV 16 at week 28.
|
Week 28
|
|
Proportion of participants with virologically-proven clearance of HPV 16 at weeks 16 and 28.
大体时间:Weeks 16、28
|
The number of participants with virologically-proven clearance of HPV 16 at weeks 16 and 28.
|
Weeks 16、28
|
|
Levels of cellular immune responses.
大体时间:Weeks 6, 16 , 28
|
Levels of cellular immune responses measured by interferon-gamma enzyme-linked immunospot (IFN-γ ELISPOT) assay in peripheral blood mononuclear cells (PBMCs) of participants at baseline and at weeks 6, 16, 28.
|
Weeks 6, 16 , 28
|
|
Proportion of participants with baseline AIN1 showing histopathological regression to no lesions at 28 weeks after the first dose.
大体时间:Week 28
|
The number of participants with AIN1 showing histopathological regression to no lesions at week 28.
|
Week 28
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Pengyuan Wang, MD、Peking University First Hospital
- 首席研究员:Zeyang Chen, MD、Peking University First Hospital
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年7月20日
初级完成 (估计的)
2026年12月30日
研究完成 (估计的)
2027年6月30日
研究注册日期
首次提交
2026年7月13日
首先提交符合 QC 标准的
2026年7月13日
首次发布 (实际的)
2026年7月17日
研究记录更新
最后更新发布 (实际的)
2026年7月17日
上次提交的符合 QC 标准的更新
2026年7月13日
最后验证
2026年7月1日
更多信息
与本研究相关的术语
其他研究编号
- NWRD09-104
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.